Open AccessTransitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability
Author(s) -
Anuj Bohra,
Qurat-Al-Ain Rizvi,
Charlotte Keung,
Abhinav Vasudevan,
Daniel R. van Langenberg
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i36.5437
Subject(s) - medicine , infliximab , inflammatory bowel disease , adverse effect , cohort , medical record , retrospective cohort study , surgery , disease
Infliximab and other intravenous biologic infusions are increasingly used for chronic disorders like inflammatory bowel disease (IBD). Rapid infliximab and home-based infusions are attractive solutions to address resource and capacity issues for infusion centres, yet infliximab infusion reactions reportedly occur in up to 25% of patients with IBD, even at the manufacturers' recommended infusion duration of 2 h.